Literature DB >> 19118897

Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations.

Stephanie R Fink1, Kimberly J Belongie, Sarah F Paternoster, Stephanie A Smoley, Animesh D Pardanani, Ayalew Tefferi, Daniel L Van Dyke, Rhett P Ketterling.   

Abstract

The PDGRFA locus has become a gene of interest based on mutational activation in various myeloid neoplasms and the availability of targeted therapies (i.e., imatinib mesylate) to its overexpression. We studied a new FISH method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocation in patients with myeloid neoplasms associated with eosinophilia. A total of 46 specimens were studied, including 15 from patients with a CHIC2 abnormality and six patients with an abnormality involving PDGFRA. Our results revealed this new FISH assay accurately detects these abnormalities and will be a useful clinical test for patients with myeloid neoplasms and eosinophilia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19118897     DOI: 10.1016/j.leukres.2008.11.016

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  2 in total

Review 1.  Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Authors:  Ayalew Tefferi; Jason Gotlib; Animesh Pardanani
Journal:  Mayo Clin Proc       Date:  2010-01-06       Impact factor: 7.616

2.  t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity.

Authors:  Sarah B Mueller; Paola Dal Cin; Long P Le; Dora Dias-Santagata; Jochen K Lennerz; A John Iafrate; Hetal Desai Marble; Andrew M Brunner; Matthew J Weinstock; Marlise R Luskin; Daniel J De Angelo; Richard M Stone; Valentina Nardi
Journal:  Blood Adv       Date:  2022-01-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.